EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy delivery
Journal of Cell Biology · 07.09.2026 · 225 (9)
DOI: 10.1083/jcb.202507217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Biology, online erschienen am 11.08.2026. Verfasst von Sergi Marco und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research UK Scotland Institute , Glasgow, UK. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Endosomes, Receptor, EphA2, Hyaluronan Receptors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Breast Cancer Now, Medical Research Council.
Abstract (Originalsprache)
The potential for using therapeutic antisense oligonucleotides (ASOs) has been hampered by a lack of understanding of how they enter cells and subsequently access their targets. Endocytosis contributes to ASO uptake, but the machinery mediating subsequent ASO trafficking to permit suppression of their target mRNAs has not been described. Here, we show that direct ASO engagement with a scavenger receptor (CD44) activates the ERK-RSK axis to promote serine phosphorylation of a receptor tyrosine kinase (EPHA2). Serine phosphorylation of EPHA2 permits endocytosis, trafficking, and accumulation of ASOs in nuclear-captured endosomes. These endosomes are then subject to lipid peroxidation and become leaky, allowing ASOs to escape and effectively suppress target mRNA expression. Inhibition of stress granule-mediated repair of these leaky endosomes further enhances ASO effectiveness. These data identify an endocytic route to the nucleus which may be exploited to maximize the effectiveness of ASO-mediated therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Research UK Scotland Institute , Glasgow, UK.
- School of Cancer Sciences, University of Glasgow , Glasgow, UK.
- Ionis Pharmaceuticals Inc. , Carlsbad, CA, USA.
- ADARx Pharmaceuticals Inc. , San Diego, CA, USA.
- Beatson West of Scotland Cancer Centre , Glasgow, UK.
ORCID-Profile: Sergi Marco, Peter J Walsh, Alexey S Revenko, Tobias Schmidt, Peter A Thomason, Lynn McGarry, A Robert MacLeod, Sonam Ansel, Dina Tataran, Martin Bushell, Chiara Braconi, Jim C Norman
Förderung
- Cancer Research UK
- Breast Cancer Now
- Medical Research Council
- Cancer Research UK Glasgow Centre
- Cancer Research UK Scotland Institute
Zitieren
APA
Marco, S., Walsh, P. J., Revenko, A. S., Schmidt, T., Thomason, P. A., McGarry, L., MacLeod, A. R., Ansel, S., Tataran, D., Bushell, M., Braconi, C., & Norman, J. C. (2026). EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy delivery. Journal of Cell Biology, 225(9). https://doi.org/10.1083/jcb.202507217
Vancouver
Marco S, Walsh PJ, Revenko AS, Schmidt T, Thomason PA, McGarry L, et al. EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy delivery. Journal of Cell Biology. 2026;225(9). doi:10.1083/jcb.202507217
BibTeX
@article{Marco2026,
author = {Marco, Sergi and Walsh, Peter J and Revenko, Alexey S and Schmidt, Tobias and Thomason, Peter A and McGarry, Lynn and MacLeod, A Robert and Ansel, Sonam and Tataran, Dina and Bushell, Martin and Braconi, Chiara and Norman, Jim C},
title = {EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy delivery},
journal = {Journal of Cell Biology},
year = {2026},
volume = {225},
number = {9},
doi = {10.1083/jcb.202507217}
}
EUVIMED